--- title: "The Smartest Growth Stock to Buy With $100 Right Now" description: "Novo Nordisk (NVO) is highlighted as a top growth stock to buy for under $100, despite recent challenges and a decline in share price. The company maintains a strong position in the diabetes drug mark" type: "news" locale: "en" url: "https://longbridge.com/en/news/260886574.md" published_at: "2025-10-13T11:26:03.000Z" --- # The Smartest Growth Stock to Buy With $100 Right Now > Novo Nordisk (NVO) is highlighted as a top growth stock to buy for under $100, despite recent challenges and a decline in share price. The company maintains a strong position in the diabetes drug market, holding a 32.6% market share. Its sales increased by 16% year-over-year, and it has promising drugs in development, including UBT251 and CagriSema. With a forward P/E of 14 and a dividend yield of 2.9%, Novo Nordisk presents an attractive investment opportunity for growth and income seekers. One of the great things about equity markets is that excellent stocks can be had at almost any price, making them accessible to most people. Even with $100, it's possible to find outstanding, growth-oriented companies to invest in. Of course, what qualifies as "the smartest" stock to buy with any amount of money will differ from one investor to the next, depending on factors such as risk tolerance, goals, and investment horizon. One growth stock trading for well below $100 that can meet many investors' demands is **Novo Nordisk** (NVO -2.96%). Here is why the Denmark-based company is an excellent stock to buy right now. Image source: Getty Images. ## A wonderful contrarian opportunity Quality growth stocks tend to be highly sought after. There is often a higher demand for shares of these companies than are available. That's why their prices rise. Sometimes, though, these otherwise excellent companies encounter challenges that lead to a sell-off, providing investors with a wonderful opportunity to pick up their shares at a discount. In my view, that's what we have with Novo Nordisk. True, the company has faced some challenges, and it has paid for them as shares have remained southbound for over a year. Its financial results haven't been as strong as expected. It hit a series of surprising clinical setbacks while losing market share to its rival, **Eli Lilly**. However, Novo Nordisk's prospects remain very strong. Novo Nordisk's claim to fame is that it has been a major player in the diabetes drug market for decades. That remains the case. As of May, it had a 32.6% share of the diabetes market and a 51.9% share of the GLP-1 space. While its hold in these fields declined compared to last year, it remains a dominant force in both. Novo Nordisk also continues to post competitive financial results for a pharmaceutical giant. The company's sales for the first half of the year increased by a strong 16% year over year to 154.9 billion Danish kroner ($24.2 billion). Further, the diabetes and obesity drug markets are rising fast due to several factors. Both conditions have skyrocketed in recent decades, and drugmakers are now developing highly innovative therapies to address them. Novo Nordisk is still at the forefront of this race. Even if the company has a smaller slice of the pie, that's not a significant problem if the pie is substantially larger. Can Novo Nordisk continue to launch innovative medicines and stay ahead of most of its peers, excluding Eli Lilly? The company's pipeline suggests that it can, and could even catch up with its eternal rival. Consider Novo Nordisk's potential triple agonist (a medicine that mimics the action of three gut hormones), UBT251. In a 12-week phase 1 study, UBT251 resulted in an average weight loss of 15.1% at the highest dose. The usual caveats regarding early-stage studies apply. Still, UBT251 looks promising, especially since there is no single triple agonist approved for weight loss yet. And that's just the tip of the iceberg. Novo Nordisk has several other exciting candidates through all phases of clinical development. And those that have already passed phase 3 studies, such as CagriSema, should generate massive sales for the drugmaker. According to some projections, CagriSema could rack up $15.2 billion in revenue by 2030. Ozempic and Wegovy, Novo Nordisk's current bestsellers, should also remain among the top-selling medicines in the world through the end of the decade. So, Novo Nordisk's medium-term outlook seems promising. ## There are more reasons to buy Novo Nordisk appeals to growth-oriented investors, but it is also a great pick for dividend seekers and bargain hunters. For those seeking income stocks, the Denmark-based drugmaker is a great choice, given its strong track record. The company's forward yield is not exceptional at 2.9% -- although that's much better than the **S&P 500**'s average of 1.3% -- but Novo Nordisk has consistently increased its dividends over the past decade. NVO Dividend (Annual) data by YCharts Finally, Novo Nordisk's shares are trading at 14 times forward earnings, whereas the average for the healthcare industry is 17.3. Even with the challenges it has faced recently, Novo Nordisk's strong pipeline and lineup, solid revenue growth, and excellent prospects in diabetes and weight management make the stock highly attractive. The company's shares are changing hands for about $59, so $100 can afford you one of them. ### Related Stocks - [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 高盛：诺和诺德定价压力被市场过度定价，口服 Wegovy 将是扭转信心的关键 | 高盛称，当前股价已完全消化 2026 财年最悲观预期。市场低估了 Medicare 放开的销量潜力和口服版 Wegovy 的收入前景。口服 Wegovy 上市表现强劲，已开出 5 万张处方，其中 9 成为自费需求，显示刚性市场潜力，将成为扭 | [Link](https://longbridge.com/en/news/275095024.md) | | 诺和诺德 ADR 恢复交易，瞬间跳水，跌幅扩大至 8.4% | 诺和诺德 ADR 恢复交易，瞬间跳水，跌幅扩大至 8.4%。风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此 | [Link](https://longbridge.com/en/news/274689185.md) | | 诺和诺德公司计划开始销售其减肥重磅药物 Wegovy 的瓶装版本 - 彭博社 | 诺和诺德公司计划开始以小瓶形式销售其减肥畅销药 Wegovy - 彭博新闻 | [Link](https://longbridge.com/en/news/275654518.md) | | 在近期股价回调和回报表现不一的情况下，评估诺和诺德公司（CPSE:NOVO B）的估值 | 诺和诺德公司 (CPSE:NOVO B) 的回报表现不一，最近上涨了 1.7%，但在过去一个月内下跌了 17.6%。截至目前，股价下跌了 5.6%，过去一年总股东回报下降了 42.5%。分析师建议的公允价值为每股 851.04 丹麦克朗，表 | [Link](https://longbridge.com/en/news/275941659.md) | | 诺和诺德公司首席财务官 Karsten Munk Knudsen 出售了价值超过 830 万丹麦克朗的股票 | 诺和诺德公司（Novo Nordisk A/S）宣布，首席财务官卡斯滕·穆克·克努森（Karsten Munk Knudsen）于 2026 年 2 月 10 日以每股 DKK 315.60 的价格出售了 26,246 股，交易总额为 DK | [Link](https://longbridge.com/en/news/275652909.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.